Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…Apraclonidine in the treatment of ptosis
Objective: To describe the improvement in ptosis with apraclonidine in patients with botulinum toxin (BoNT) induced ptosis. Background: Ptosis is a manifestation of a variety…The systemic synuclein sampling study (S4)
Objective: The Systemic Synuclein Sampling Study (S4) is designed to characterize the distribution of alpha-synuclein (α-syn) pathology in multiple tissues and biofluids in Parkinson's disease…Active movement discrimination of the ankle in Parkinson’s disease
Objective: To determine (1) whether people with Parkinson's disease (PD) experience an impaired sense of proprioception in the ankles and (2) if this relates to…Applicability study of a multitask cognitive and motor exercise program for individuals with Parkinson´s disease: The COGWEB CNS Move Program
Objective: To test the applicability of a new rehabilitation program for people with Parkinson´s disease combining web-based cognitive training with motor exercises. Background: Parkinson´s disease…Systematic literature review of quetiapine for hallucinosis / psychosis in Parkinson’s disease (PD)
Objective: To conduct a systematic review to evaluate the efficacy, safety, and dosing range of quetiapine for the treatment for hallucinosis / psychosis in patients…A double-blind randomized controlled trial of cognitive training for freezing of gait in Parkinson’s disease
Objective: To investigate the potential of cognitive training to improve symptoms of freezing of gait in Parkinson's disease. Background: Freezing of gait (FOG) is a…Development of a human neuroblastoma model of pantothenate kinase-associated neurodegeneration
Objective: To establish a stable human neuronal model defective in PanK2. Background: Pantothenate Kinase-Associated Neurodegeneration (PKAN), is caused by mutations in PANK2, which encodes one…A healthy volunteer phase 1 study of RE-024, a potential phosphopantothenate replacement therapy for patients with pantothenate kinase-associated neurodegeneration (PKAN)
Objective: To assess the safety, tolerability, and pharmacokinetics of single oral doses of RE-024 in healthy adult volunteers. Background: PKAN is a rare, autosomal recessive,…Significant improvement of adult-onset dystonia with cannabinoids-based oromucosal spray
Objective: We performed an open study of delta-9-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray (Nabiximols, Sativex®) in 6 patients with suboptimal responsive adult-onset dystonia. Background: Cannabinoids…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.